Characteristics and survival of metastatic colorectal cancer patients receiving local treatment with deficient mismatch repair versus proficient mismatch repair

Deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC) forms a distinct biological subgroup with prognostic, predictive and therapeutic implications compared to proficient MMR (pMMR) mCRC. It is unclear whether local therapy is similarly effective for dMMR mCRC patients. The aim of this study is to describe the recurrence-free survival (RFS) and overall survival (OS) after first-line local treatment in dMMR versus pMMR patients in the pre-immunotherapy era.